Vaughn Himes - Seattle Genetics Insider

Seattle Genetics Inc -- USA Stock  

USD 54.12  3.17  6.22%

Executive VP of Process Sciences and Technical Operations

Dr. Vaughn B. Himes, Ph.D. serves as Chief Technical Officer of the Company. He was Executive Vice President Technical Operations and Process Sciences of Seattle Genetics, Inc. Dr. Himes joined Seattle Genetics as Executive Vice President, Technical Operations in April 2009 and has served as our Executive Vice President, Technical Operations and Process Science since July 2012. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo
Age: 55  EVP Since 2016  Ph.D    
Himes received a Bachelor of Arts in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.

Vaughn Himes Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (14.26) % which means that it has lost $14.26 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (19.14) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 8 records

EVP Since

John CapekAbbott Laboratories
Thomas FreymanAbbott Laboratories
Stuart ArbuckleVertex Pharmaceuticals Incorpor
Brian BlaserAbbott Laboratories
Hubert AllenAbbott Laboratories
Susan HallEndo International plc
Giovanni MagniBio Rad Laboratories Inc
Richard AshleyAbbott Laboratories

Entity Summary

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington. Seattle Genetics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 1100 people.Seattle Genetics Inc (SGEN) is traded on NASDAQ in USA. It is located in WASHINGTON, U.S.A and employs 1,100 people. Seattle Genetics is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run My Watchlist Analysis Now

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Hide  View All  NextLaunch My Watchlist Analysis

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Seattle Genetics Inc to your portfolio

Top Management

Seattle Genetics Inc Leadership Team
Pinkston Peggy, Director
David Gryska, Director, MBA
Vaughn Himes, EVP, Ph.D
Daniel Welch, Director, MBA
Felix Baker, Director, Ph.D
Srinivas Akkaraju, Director, Ph.D
Alpna Seth, Director
Nancy Simonian, Director, Ph.D
Marc Lippman, Director
Peggy Pinkston, Executive
Jonathan Drachman, President
Jean Liu, President
Robert Lechleider, President, Ph.D
Clay Siegall, Chairman, Ph.D
Darren Cline, President, MBA
Dennis Benjamin, President, Ph.D
Eric Dobmeier, COO
John Orwin, Director, MBA
Todd Simpson, CFO
John McLaughlin, Director

Stock Performance

Seattle Genetics Performance Indicators